Cowen & Co. Maintains a Hold Rating on Zafgen (ZFGN)

By Carrie Williams

In a report released today, Yaron Werber from Cowen & Co. maintained a Hold rating on Zafgen (ZFGNResearch Report). The company’s shares opened today at $2.29, close to its 52-week low of $1.88.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 12.2% and a 59.8% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zafgen with a $7 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $12.36 and a one-year low of $1.88. Currently, Zafgen has an average volume of 284.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases.